Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am an analyst and CFA Charterholder that gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
Paul is a stock investor with an accounting/finance background. He likes to look for value growth stocks and momentum news plays. He is also known as Superman on Twitter @super_trades and his blog is www.super-trades.com (http://www.super-trades.com).
This page and all of its contributor content is operated by Quoth the Raven Research, LLC. Quoth the Raven is Christopher Irons from Philadelphia, PA. Equity research and analysis performed by QTR has been featured in Barron's, the Wall Street Journal, Financial Times, Yahoo Finance, Reuters, Bloomberg and many other financial outlets. QTR is a speaker at numerous financial conferences annually. QTR was named to Benzinga's "10 Financial Twitter Names to Follow in 2018" and in late 2017 was named to Forbes' "Top 100 Twitter Accounts for Finance". In 2016, QTR's work was selected as a finalist for the Sohn Investment Conference Idea Contest. In 2014, he was named to Seeking Alpha's Top List of Best Performing Financial Bloggers and was TipRanks' #6 Performing Financial Blogger (Out of 4,000+). View QTR's track record on TipRanks: https://www.tipranks.com/bloggers/quoth-the-raven View QTR's website: http://www.quoththeravenresearch.com View QTR's Twitter: https://twitter.com/QTRResearch Listen to the QTR podcast: http://quoththeraven.podbean.com All content contained herein is bound to both Seeking Alpha's terms of service, as well as the terms of service found here: https://quoththeravenresearch.com/disclaimerterms-of-service/
Helix Investment Research was founded in July 2011 by Ivan Deryugin, and focuses on leveraging secular global trends, across a variety of sectors, in order to generate long-term outperformance.
The Life Sciences Report features leading investment coverage of the life sciences sector, including biotechnology, pharmaceuticals, tools & diagnostics, and medical devices. A Streetwise Reports publication. www.TheLifeSciencesReport.com
One of the first stocks Michael Goode looked to invest in when he first started investing in 2005 was a small company traded on the Pinksheets called US WindFarming. During his research, Michael found out that the CEO had previously been convicted of criminal stock fraud and had served time in jail for a scheme that purported to turn base metals into gold. Michael decided not to invest and six months later the SEC sued the company, alleging that all the press releases were fake and the company was a sham that existed for the sole purpose of selling shares to gullible investors in order to enrich the insiders.
Following that experience, Michael Goode became a bit of a cynic. While he called himself a value investor and even briefly ran a value investing newsletter, his true love was exposing fraud and failed businesses. At his blog GoodeValue.com, sometimes syndicated on SeekingAlpha.com, he blasted companies such as H2Diesel (later renamed New Generation Biofuels), Cytocore (later sued by the SEC), Remote MDX (later panned by Andrew Left of Citron Research and Carol Remond of Dow Jones Newswires), and Noble Roman’s Pizza (on which he was quoted in multiple articles in the Indianapolis Business Journal).
Michael Goode has continued to shine a light on stock promotions and the people behind them on his trading blog, GoodeTrades.com. He has blogged about lawsuits involving stock promoters (a couple more) and he has exposed the multiple websites used by certain stock promoters. He remains a full-time stock trader; you can see most of his trades on Profit.ly.
Michael Goode graduated from Earlham College in 2004 and obtained a Masters Degree in Cognitive Psychology in 2007, from Washington University in St. Louis. He is the managing member of MorningLightMountain LLC, the owner of GoodeTrades.com, OTCMicroCapResearch.com, and all other content he writes online. Michael Goode has never been charged with or convicted of any crime whatsoever.
Biomed Group is an independent research group, with a goal of providing investors with real-time information and exclusive specialised research on biotechnology stocks, so that they can make informed investment decisions.
Mike Havrilla is a former pharmacist, biotech stock trader, and writer with experience that includes full-time online trading since 2009, working as a full-time pharmacist from 2004-2009, and writing for investors since 2007. Mike merged his former publishing business with BioRunUp.com / Mark Messier in October 2010, creating a new online biotech stock research and trading service--please send me a direct message if you are interested in a discount promo code for 43% savings on a one-year subscription.
For the past 30 years, I have been involved in startups, as a founder, and active investor. My first company was purchased by Johnson & Johnson, which set the foundation for future investments. By focusing on startups I learned the advantage of investing in promising companies before they became household names. My interest in startups has never waned, and has become my primary focus today.
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Prescience Point Capital Management conducts in-depth investigations of public companies, which often uncover fraud, misleading business practices or significant valuation issues. Unlike conventional investment research, we spend months on our analysis, dig deep into a company’s numbers, speak to industry experts and conduct on-the-ground due diligence to form our views. Our investment opinions are based on verifiable facts, not management’s representation of those facts.
Ivy League grad, summa cum laude, 4.0 in Economics, Columbia J.D., 20+ years experience identifying early trends and themes b4 the Wall St herd. In search of undervalued, underfollowed, explosive growth opportunities, principally in, but not limited to, the biotech sector.
The Fraud Research Institute ("FRI") specializing in the research and discovery of financial scandals and corporate malpractice in the United States with an emphasis on the small cap markets.
Our business model is to publish the highest quality and most compelling professional research reports that highlight all material information necessary for short-biased traders to identify superior risk-to-reward trade ideas that are primarily a result of market inefficiencies created by the artificial demand from stock promotion (pump & dump) campaigns.
We identify Wall Street's biggest frauds and profit from them.
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces a Daily Ratings Report, Weekly Newsletter, and offers real-time insider data and analytics via its institutional strength Data Module and APIs. InsiderInsights' research and data are further available on Bloomberg terminals at ININ and APPS ININ .
Mr. Moreland is also principal of Insider Asset Management llc, a registered investment adviser in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of "Profit From Legal Insider Trading" (Dearborn 2001).
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
"The truth is incontrovertible. Malice may attack it, ignorance may deride it, but in the end, there it is." - Winston Churchill
Starting 3/2/13 future articles may either be authored by myself or members of my investing club. Thank you for reading!
Alex Daley is the senior editor of Casey’s Extraordinary Technology. In his varied career, he’s worked as a senior research executive, a software developer, project manager, senior IT executive, and technology marketer.
He’s a technologist who has collaborated on the development of cutting-edge technologies, including: remote lie detectors that work invisibly across a room, autonomous/robotic vehicles that can drive themselves unaided across hundreds of miles of rugged desert terrain, computer vision systems that enable computers to understand the depth in 2D photographs, lightweight composite ceramics that can withstand artillery fire better than metal, maps of the human genome, automated analysis of video for non-verbal communication cues, and face detection and recognition for spotting people in photos and surveillance videos.
But Alex’s technological experience is only half the story. He’s an industry insider of the highest order, having been involved in numerous startups as an advisor to venture capital companies. He’s a trusted advisor to the CEOs and strategic planners of some of the world’s largest tech companies. And he’s a successful angel investor in his own right, with a long history of spectacular investment successes.
Whether you are a large or small firm, GeoInvesting will cater to your needs and create a sound process for corporate diligence. Our specialty is Information Arbitrage: finding the hidden bits of insight that give an advantage, especially in the vast realm of microcaps that others ignore.
To accomplish this we choose to work closely with you so you can be kept abreast of the progress of our due diligence from start to finish, making sure that we cultivate a relationship of trust between our team and yours.
Who Can We Help Specifically?
We actually do not limit ourselves to any specific group. We have worked at great lengths with:
>High Net Worth Investors
>Private & Public M&A
>Other Due Diligence Firms
There is really no one that we can’t work with since we’ve covered just about every facet of the due diligence process, whether it be on-the-ground or “through the files.” We can even tailor our services to your specific requirements.
We have a retail solution for everyone – the long investor, the short investor, the pump and dump investor and the every day trader that is interested in the micro cap arena. We’ve shown that we can overcome the challenges posed by any market environment, quickly seizing investment and trading opportunities as they arise. Because of this, our Premium members have been able to enjoy above-average returns on our ideas. Our solutions enable us to cater to what matters to you the most.
Do you want access to reports that can convey the proper valuation of equities, reports that can immediately convince the market that these valuations are warranted? Do you want information arbitrage that allows you to be among the first to take action based on the intel? Do you need daily ideas, some of which have proven to be some of the most rewarding calls to action that the GeoTeam has offered? Would you like to follow our GeoBargains and select trades? Or do you just need to be part of an exclusive twitter following that receives alerts before the rest of the market?
If you have answered yes to any of the questions above, then don’t wait any longer. Join our Network and see why our following continues to grow on a daily basis. The faster you join, the more likely you will be among the first to harness the power of our offering.
Sign up today and start to get:
>Education on investing, both financial and psychological
>Access to the GeoTeam through our exclusive chatroom.
See GeoInvesting Micro Insights on Seeking Alpha Marketplace